Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns)
Vanessa L. Beesley(QIMR Berghofer Medical Research Institute), Michael Friedländer(Prince of Wales Hospital), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Anna DeFazio(The University of Sydney), Rachel Campbell(South Eastern Health and Social Care Trust), Christina M. Nagle(The University of Queensland), Peter Grant(The University of Melbourne), Andreas Obermair(Royal Brisbane and Women's Hospital), Tanya L. Ross(QIMR Berghofer Medical Research Institute), Madeleine King(The University of Sydney)
Cited by 36
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k